LONDON, UK: GSK plc (LSE/NYSE: GSK) it intends to sell approximately 385 million ordinary shares in Haleon, equivalent to approximately 4.2% of Haleon’s issued share capital and representing GSK’s entire shareholding in Haleon.
Following the successful demerger and premium listing of Haleon plc as announced on 18 July 2022, GSK initially retained a 12.94% (Excluding shares in Haleon held by the GSK employee share ownership trust) stake in Haleon.
As a result of the disposals announced on 12 May 2023, 6 October 2023 and 16 January 2024, GSK has since sold a total of 810m ordinary shares in Haleon, reducing its stake in Haleon to approximately 4.2%.
The disposal announced today will be conducted through a placing of ordinary shares in Haleon to institutional investors. The offer price will be determined by means of an accelerated bookbuild offering process which is to start immediately.
GSK has entered into a secondary block trade agreement with BofA Securities (“BofA”) and Goldman Sachs International (“Goldman Sachs”) under which BofA and Goldman Sachs have been appointed to act as the Joint Global Coordinators of the Offering.
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Pfizer announces major share sale in Haleon plc alongside a strategic share buyback